CORRECTING and REPLACING ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
April 29 2024 - 5:00PM
Business Wire
GanNA founders include Carolyn Bertozzi,
Ph.D., Richard D. Cummings, Ph.D., Ryan A. Flynn, M.D., Ph.D., and
Namita Bisaria, Ph.D., M.B.A.
Additional investment strengthens ReNAgade’s
delivery platform with unique conjugation platform based on novel
glycobiology
Please replace the release dated April 26, 2024 with the
following corrected version due to multiple revisions.
The updated release reads:
RENAGADE THERAPEUTICS CONTINUES COMMITMENT
TO GANNA BIO AND GLYCAN BIOLOGY
GanNA founders include Carolyn Bertozzi, Ph.D.,
Richard D. Cummings, Ph.D., Ryan A. Flynn, M.D., Ph.D., and Namita
Bisaria, Ph.D., M.B.A.
Additional investment strengthens ReNAgade’s
delivery platform with unique conjugation platform based on novel
glycobiology
ReNAgade Therapeutics, a company unlocking the limitless
potential for RNA medicines, today announced its ongoing commitment
to unlock the potential of glycobiology through support for ongoing
research at GanNA Bio, and an integration of the key founders of
GanNA Bio into the ReNAgade ecosystem.
GanNA Bio was formed in 2021 and invested in by ReNAgade to
harness novel glycobiology to enable extra-hepatic RNA delivery
based on pioneering research licensed from Stanford University,
Boston Children’s Hospital, and Beth Israel Deaconess Medical
Center, which was developed in the labs of Carolyn Bertozzi, Ph.D.,
winner of the 2022 Nobel Prize in Chemistry and Professor of
Chemistry in the Stanford School of Humanities and Sciences; Ryan
A. Flynn, M.D., Ph.D., Assistant Professor at Boston Children’s
Hospital; and Richard D. Cummings, Ph.D., S. Daniel Abraham
Professor of Surgery at Beth Israel Deaconess Medical Center, and
led by Namita Bisaria, Ph.D., M.B.A., a serial entrepreneur in the
RNA therapeutics field. Its platform, based on new advances in
glycobiology and synthesis, uses cell-specific glycans to develop
next-generation conjugates and to unlock the delivery of short and
long stranded RNA medicines.
“ReNAgade will continue to benefit tremendously from GanNA’s
promising work in developing extra-hepatic delivery technology that
helps expand the breadth and potential of our own RNA medicines,”
said Brian Goodman, Co-founder of ReNAgade. “Delivery is
foundational to ReNAgade’s mission to overcome the current
limitations of RNA medicines. We believe the technology developed
within GanNA will help further solidify ReNAgade’s leadership
position as we continue advancing our unique, integrated
therapeutic platform.” GanNA founders Bertozzi and Cummings will
now serve as advisors to ReNAgade.
“The progress in glycoRNA science from our seminal publication
in the journal Cell is moving fast, and integration with ReNAgade’s
pipeline will strengthen our position to develop a broad portfolio
of cell specific delivery systems, leveraging the latest
developments in glycobiology in order to expand the array of
addressable diseases of RNA medicines,” said Ryan Flynn.
Dr. Bertozzi added, “The combination of GanNA’s innovative
glycobiology-based targeting strategy with ReNAgade’s experience in
the development of RNA medicines will be a powerful combination for
the benefit of patients.” Dr. Cummings noted that
“Glycobiology-based RNA medicines represent a new frontier, and it
is rewarding to see the possibilities of ReNAgade developing these
for clinical use.”
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to
treat disease anywhere in the body. We combine our novel RNA
delivery platforms with a comprehensive RNA platform allowing for
an all-RNA system for coding, editing, and gene insertion to
develop new medicines.
To accelerate the future of medicine, we bring together a team
with deep RNA and delivery expertise to develop paradigm-shifting
RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and
its leadership, visit www.renagadetx.com
About GanNA Bio
GanNA was created by Drs. Flynn and Bisaria, and invested by
ReNAgade in 2021 following a sponsored research agreement in the
lab of Dr. Flynn. The mission is to explore the potential of novel
glycobiology therapies following the pioneering work at Stanford
University by Drs. Flynn and Bertozzi on glycoRNA. The GanNA Bio
Scientific Advisory Board included Drs. Bertozzi, Cummings, Flynn,
and ReNAgade CSO, Pete Smith.
University Conflict of Interest Disclosure Drs. Bertozzi,
Cummings and Flynn consult for ReNAgade Therapeutics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240426251202/en/
Investor Relations Contact: Emily Brabbit, Argot Partners
(212) 600-1902 renagade@argotpartners.com Media Relations
Contact: Sarah Sutton, Argot Partners (212) 600-1902
renagade@argotpartners.com